Zimbabwe's Ministry of Health and Child Care began a nationwide rollout of the long‑acting injectable antiretroviral therapy cabotegravir on Feb. 23, 2026, making it one of the first countries to move the drug from trial settings into routine care.
Cabotegravir, approved by the World Health Organization in 2024, is administered as an injection every two months and is intended to improve adherence compared with daily oral regimens; the country currently has about 1.4 million people living with HIV, according to UNAIDS data.
What the Left Is Saying
President Emmerson Mnangagwa said the rollout demonstrates Zimbabwe’s commitment to cutting new HIV infections, noting, “We are proud to bring this breakthrough treatment to our people and to lead the region in innovative health solutions.” The statement was released by the President’s office on Feb. 23.
The Treatment Action Campaign, a South‑African HIV advocacy group, welcomed the move, calling it “a vital step toward ending the epidemic by reducing missed doses and stigma associated with daily pills.” The group cited the drug’s potential to boost viral suppression rates.
What the Right Is Saying
Opposition leader Nelson Chamisa cautioned that the program’s $150 per dose cost could strain Zimbabwe’s already limited health budget, saying, “We must ensure that scaling up does not divert resources from other essential services.” The comment was made at a parliamentary health committee hearing.
A spokesperson for the Heritage Foundation noted that while the drug is promising, “Donor‑dependent nations should carefully assess long‑term financing plans before committing to widespread rollout.” The comment was posted on the foundation’s website on Feb. 24.
What the Numbers Show
UNAIDS estimates that 12.9 % of Zimbabwe’s adult population was living with HIV in 2022, amounting to roughly 1.4 million people; of those, about 86 % were on antiretroviral therapy, according to the latest country progress report.
WHO pricing data released in 2024 list the average cost of cabotegravir at $150 per injection, translating to $900 per year per patient, compared with $200‑$300 for standard oral regimens in low‑income settings.
The Bottom Line
The rollout positions Zimbabwe as a regional pioneer in long‑acting HIV treatment, but its success will depend on sustained financing, supply‑chain management, and monitoring of adherence outcomes; observers will watch early results to gauge scalability for other low‑resource countries.